Adults and children with any type of major bleeding (6 studies, n= 618).
Fresh or whole blood (containing red blood cells (RBC), plasma, and platelets) from allogeneic donors (WB group).
Blood component therapy, (RBC, and/or any forms of plasma, and/or platelets, and/or cryoprecipitate, or standard care), (BC group).
All-cause mortality at 24-hours and 30-days was reported in 3 trials. There was no evidence of a difference in mortality of WB compared to BC therapy (very-low certainty evidence). For the remaining outcomes (organ injury, mechanical ventilation and intensive care unit requirement, infection, arterial/venous thrombotic events, and haemolytic transfusion reaction) there was no difference between WB and BC therapy (very-low certainty evidence).